ArticleWorld journal of oncology2026
Survival Analysis and Treatment Strategies for Locally Advanced Lung Squamous Cell Carcinoma in Elderly Patients.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of the study was to analyze the survival and treatment strategies of elderly patients with locally advanced lung squamous cell carcinoma. Methods: A retrospective analysis was conducted on the clinical and follow-up data of 278 patients with locally advanced lung squamous cell carcinoma admitted to the Fourth Hospital of Hebei Medical University from January 2012 to December 2019. Results: The 1-, 3-, 5-, and 10-year survival rates of the entire group were 86.0%, 50.6%, 40.8%, and 24.2%, respectively. There were a total of 142 cases aged 65 or elder, with 1-, 3-, 5-, and 10-year survival rates of 83.9%, 44.3%, 32.3%, and 15.6%, respectively. Among them, the progression-free survival (PFS) of the elderly group receiving radiotherapy dose ≥ 60 Gy was significantly prolonged compared to the < 60 Gy group (although P > 0.05). Comprehensive radiotherapy and chemotherapy showed a significant trend of prolonging overall survival (OS) compared to simple radiotherapy (Breslow = 0.029, log rank = 0.126). χ Conclusion: The prognosis of locally advanced unresectable lung squamous cell carcinoma is poor, especially in elderly patients. If the patient's general condition is good, it is recommended to receive radiation therapy with a dose of ≥ 60 Gy and try comprehensive treatment with tolerable toxic side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.